K ingella kingae is the leading pathogen of osteoarticular infection (OAI) in Ͻ4-yearold children in different countries where improved culture methods and nucleic acid amplification assays are routinely employed (1). The oropharynx is recognized as the portal of entry for K. kingae, which can penetrate the bloodstream and invade distant organs, facilitated by several virulence factors, such as a recently described polysaccharide capsule (2). From an international collection of 150 invasive and carriage isolates from 10 countries, Porsch et al. (2) have described four capsule types using a multiplex PCR approach. Over 95% of invasive isolates in the collection were types a or b, while capsule types c and d were more commonly observed among carriage isolates (2, 3). This distribution was described based on K. kingae isolates; however, K. kingae is a fastidious bacterium, and whether strains harboring capsule types a or b can be more easily cultivated from clinical samples is unknown. Such differences may lead to biased epidemiological results. Moreover, among this collection, 30 invasive isolates were from France, mainly isolated from 2010 to 2013 (n ϭ 24/30, date range 1972 to 2013). To our knowledge, no more recent data are available yet, and whether the epidemiology has changed remains to be determined. We aimed to describe the K. kingae capsule serotypes using a multiplex PCR protocol, as recently described (4), on a fraction of our collection of osteoarticular samples, which were positive with the K. kingae specific real-time PCR used as routine in our laboratory (5). From July 2013 to April 2018, we found 115 K. kingae-positive osteoarticular samples from 105 patients (1 to 3 samples per patient). Sample origins were joint fluid (95/105; 90.5%), synovial biopsy specimen (8/105; 7.6%), bone abscess (1/105; 0.9%), and subcutaneous collection (1/105; 0.9%). Capsular PCR allowed unambiguously identification of a capsule type in all of these 115 samples (Fig. 1). Among the 105 patients, the PCR results showed 71 (67.6%) type a capsules, 33 (31.4%) type b capsules, 1 (0.9%) type c capsule, and no type d capsules. When multiple samples were available for one patient, the results were identical for each sample. There were no significant variations between distribution of type a and b